CiMaas receives EMA qualification for NK cell product
The Committee for Advanced Therapies (CAT) from the European Medicine Agency (EMA) has classified the NK cell technology developed by CiMaas as somatic cell […]
News
The Committee for Advanced Therapies (CAT) from the European Medicine Agency (EMA) has classified the NK cell technology developed by CiMaas as somatic cell […]